Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24152207 | 0.92 | ABCG2 (0.33) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL24118905 | 0.92 | CYP1A1 (0.34) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL23740462 | 0.92 | CYP1A1 (0.34) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL24118904 | 0.91 | CYP1A2 (0.34) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL23740398 | 0.91 | CYP1A2 (0.34) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL24363389 | 0.91 | ABCG2 (0.35) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL24152121 | 0.91 | CYP1A2 (0.33) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL24363387 | 0.90 | CYP1A1 (0.31) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL23740351 | 0.90 | CYP1A2 (0.33) | CYP1A1CYP1A2FYNMAPK3AHR | |
| SCHEMBL23740627 | 0.90 | ABCG2 (0.37) | CYP1A1CYP1A2FYNMAPK3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395263-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | LT MATERIALS CO., LTD. (KR) | 2021-12-23 | — | — | US | disclosed |
| EP-3862353-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | LT Materials Co., Ltd. (KR) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395263-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | ODC1, AOX1, CYP1B1 | CYP1A1 4/4885CYP1A2 16/4885FYN 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.